银屑病患者抗氧化能力及8-异前列腺素F2α的检测及意义

Determination of antioxidant capacity and 8？鄄iso？鄄prostaglandin F2α levels in patients with psoriasis and their significance

目的 探讨银屑病患者血清及皮损中8-异前列腺素F2？琢的水平和血清抗氧化防御水平及其与疾病严重程度的关系。方法 分光光度法测定50例寻常性银屑病患者及15例健康对照血清总抗氧化能力（T-AOC）水平及抗氧化酶包括超氧化物岐化酶（SOD）、过氧化氢酶（CAT）、谷胱甘肽过氧化酶（GSH-Px）的活性。分别采用酶联免疫吸附试验和免疫组化SP法检测患者及健康对照血清、皮损中8-异前列腺素F2？琢的表达水平。结果 银屑病患者血清T-AOC水平为（12.78 ± 7.75） U/ml，SOD活性为（28.91 ± 9.35） U/ml，GSH-Px活性为（180.64 ± 47.70） U，较健康对照组［T-AOC （23.17 ± 8.81） U/ml，SOD（51.36 ± 7.92） U/ml，GSH-Px（244.20 ± 66.68） U］显著下降（P值均 〈 0.01），且重度患者组T-AOC水平［（9.06 ± 5.30） U/ml］、SOD活性［（21.63 ± 5.28） U/ml］较轻中度患者组［T-AOC（15.27 ± 8.18） U/ml，SOD （33.76 ± 8.28） U/ml］下降更为明显（P值均 〈 0.01），轻中度患者CAT活性［（36.92 ± 11.31） U/ml］显著高于对照组［（28.55 ± 8.57） U/ml，P 〈 0.05］及重度患者［（24.15 ± 9.36） U/ml，P 〈 0.01］，患者血清及皮损中8-异前列腺素F2？琢水平［（88.77 ± 25.27） ng/L，0.0186 ± 0.0082］较健康对照组［（38.34 ± 8.94） ng/L，0.0027 ± 0.0014］升高（P值均 〈 0.01），且重度患者组［（114.24 ± 13.93） ng/L，0.0279 ± 0.0027］较轻中度患者组［（71.78 ± 14.35） ng/L，0.0125 ± 0.0030］升高更为明显（P值均 〈 0.01）。患者T-AOC水平以及SOD、CAT活性与银屑病面积和皮损严重程度指数（PASI）评分均呈负相关，r值分别为-0.384、-0.573、-0.444，P值均 〈 0.01。血清及皮损中8-异前列腺素F2？琢水平均与PASI评分呈正相关，r值分别为0.710、0.783，P值均 〈 0.01。结论 银屑病患者血清及皮损处8-异前列腺素F2？琢水平较以往的氧化应激指标或许更能反映机体氧化应激状态。

Objective To determine the levels of 8-iso-prostaglandin F2α （PGF2α） in sera and lesions as well as antioxidant capacity in sera of psoriatic patients, and to assess their correlations with disease severity. Methods Serum and skin tissue samples were collected from 15 healthy controls and 50 patients with psoriasis vulgaris. Spectrophotometry was performed to determine the levels of total antioxidant capacity （T-AOC） and the activities of antioxidant enzymes such as superoxide dismutase （SOD）, catalase （CAT） and glut-athione peroxidase （GSH-Px） in serum samples. Enzyme-linked immunosorbent assay （ELISA） and immunohis-tochemical SP method were carried out to detect the expression level of 8-iso-PGF2α in the serum and tissue specimens respectively. Results The psoriatic patients showed a significant decrease in the serum level of T-AOC （（12.78 ± 7.75） U/ml vs. （23.17 ± 8.81） U/ml, P 〈 0.01） as well as the activities of SOD （（28.91 ± 9.35） U/ml vs. （51.36 ± 7.92） U/ml, P 〈 0.01） and GSH-Px （（180.64 ± 47.70） U vs. （244.20 ± 66.68） U, P 〈 0.01） compared with the healthy controls. The serum T-AOC level and SOD activity were lower in patients with severe psoriasis than those with mild or moderate psoriasis（（9.06 ± 5.30） U/ml vs. （15.27 ± 8.18） U/ml, （21.63 ± 5.28） U/ml vs. （33.76 ± 8.28） U/ml, both P 〈 0.01）, while there was no significant difference in the activity of GSH-Px between patients with severe and mild or moderate psoriasis. The serum CAT activity was significantly higher in patients with mild or moderate psoriasis than in the healthy controls and patients with severe psoriasis （（36.92 ± 11.31） U/ml vs. （28.55 ± 8.51） U/ml and （24.15 ± 9.36） U/ml, P 〈 0.05 and 0.01）. Increased serum and lesional 8-iso-PGF2α levels were observed in psoriatic patients compared with the healthy controls （（88.77 ± 25.27） ng/L vs. （38.34 ± 8.94） ng/L, 0.0186 ± 0.0082 vs. 0.0027 ± 0.0014, both P 〈 0.01）, as well as in patients with severe psoriasis compared with those with mild or moderate psoriasis （（114.24 ± 13.93） ng/L vs. （71.78 ± 14.35） ng/L, 0.0279 ± 0.0027 vs. 0.0125 ± 0.0030, both P 〈 0.01）. The psoriasis area and severity index （PASI） score was negatively correlated with T-AOC level, SOD and CAT activities （r = -0.384, -0.573 and -0.444, all P 〈 0.01）, positively correlated with serum and lesional 8-iso-PGF2α levels（r = 0.710, 0.783, both P 〈 0.01）, and uncorrelated with GSH-Px activity. None of the parameters was correlated with the course of disease. Conclusion The serum and lesional levels of 8-iso-PGF2α may be a more sensitive marker for oxidative damage and disease severity.